Amgen Takes Back Rights to Prolia, Xgeva and Vectibix Drugs
December 14 2015 - 5:50PM
Dow Jones News
By Maria Armental
Amgen Inc. will take back rights to osteoporosis drug Prolia and
cancer drugs Xgeva and Vectibix under a deal with GlaxoSmithKline
PLC.
Financial terms weren't disclosed.
Amgen said the deal, which include key markets such as Brazil
and China, would add to profit in 2017.
GlaxoSmithKline has held regional rights to Prolia and Xgeva
since 2009 and to Vectibix since 2010.
Xgeva and Prolia are the same drug, denosumab, but are given at
different doses for different uses. Prolia is given twice a year to
treat osteoporosis, while Xgeva is used monthly to help prevent
bone-related complications in certain advanced cancer patients.
In April 2014, Amgen took over rights to denosumab for
osteoporosis indications in the European Union, Russia, Mexico and
other countries.
For the year ended Dec. 31, 2014, Amgen reported a combined
$2.25 billion in Xgeva and Prolia sales, up 28% from the year
earlier, and $505 million from Vectibix, up nearly 30% from the
year earlier.
Thomas Gryta contributed to this article.
Write to Maria Armental at maria.armental@wsj.com
(END) Dow Jones Newswires
December 14, 2015 17:35 ET (22:35 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Apr 2023 to Apr 2024
